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Abstract: 
Aims: Studies consistently identify substance treatment populations as more likely to 
die prematurely compared with age-matched general population, with mortality risk 
higher out-of-treatment than in-treatment. While opioid-using pharmacotherapy 
cohorts have been studied extensively, less evidence exists regarding effects of other 
treatment types, and clients in treatment for other drugs. This paper examines 
mortality during and following treatment across treatment modalities. 
Methods: A retrospective seven-year cohort was utilised to examine mortality during 
and in the two years following treatment among clients from Victoria, Australia, 
recorded on the Alcohol and Drug Information Service database by linking with 
National Death Index. 18,686 clients over a 12-month period were included. Crude 
(CMRs) and standardised mortality rates (SMRs) were analysed in terms of treatment 
modality, and time in or out of treatment. 
Results: Higher risk of premature death was associated with residential withdrawal as 
the last type of treatment engagement, while mortality following counselling was 
significantly lower than all other treatment types in the year post-treatment. Both 
CMRs and SMRs were significantly higher in-treatment than post-treatment. 
Conclusion: Better understanding of factors contributing to elevated mortality risk 
for clients engaged in, and following treatment, is needed to ensure that treatment 
systems provide optimal outcomes during and after treatment. 
Keywords: mortality, treatment, cohort, linkage, drug  
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1 Introduction 
In 2011/12, it is estimated that between 202, 168 and 232, 419 Australians received 
alcohol and other drug treatment (AOD) (Chalmers, Ritter, & Berends, 2016). 
Alcohol and other drug treatments take various forms (e.g. pharmacological 
detoxification, psychosocial interventions) and are delivered through a range of public 
and private service providers (Chalmers et al., 2016). While supporting evidence 
varies across modalities, there is widespread agreement that individuals who engage 
with treatment services are more likely to significantly reduce or cease drug use and 
remain drug free than those who do not undertake treatment (Corsi, Lehman, & 
Booth, 2009; Madras et al., 2009; Maremmani, Pani, Pacini, & Perugi, 2007; World 
Health Organisation, 2008). Drug use cessation is associated with improvements in 
general health, mental health and social functioning (Corsi et al., 2009; Department of 
Health (England), 2007; Kimber et al., 2010; Madras et al., 2009). Yet, there is also 
risk associated with treatment engagement and drug use cessation. Evidence suggests 
that among opioid, heroin and alcohol treatment attendees in particular, mortality 
rates peak within the first four weeks following treatment cessation (Buster, Brussel, 
& Brink, 2002; Cousins et al., 2011; Degenhardt et al., 2009; Strang et al., 2003)  
Examination of mortality outcomes for drug users indicates that treatment 
engagement is protective against premature mortality; that is mortality rates are lower 
when users are in treatment than prior to or indeed following treatment cessation 
(Darke, Mills, Ross, & Teesson, 2011; Degenhardt et al., 2009). The period 
immediately after discharge from residential detoxification (Strang et al., 2003) or 
following incarceration (Farrell & Marsden, 2008; Ødegård, Amundsen, Kielland, & 
Kristoffersen, 2010; Seaman, Brettle, & Gore, 1998), has been associated with 
sharply elevated overdose fatality risk. Indeed, clients whose drugs of choice are 
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central nervous system CNS depressants (alcohol or heroin) prior to entry into 
detoxification treatment have higher mortality risk following treatment, when 
compared with clients whose primary drugs are stimulants (Saitz et al., 2007). 
Relapse after detoxification represents a specific risk due to a sharp reduction in 
tolerance. 
Opioid-using cohorts receiving pharmacotherapy are the most extensively studied 
group in regards to post-treatment mortality. For instance, Degenhardt (2009) found 
that opioid pharmacotherapy clients had an in-treatment crude mortality rate (CMR) 
of 6.0 (95% CI: 5.7–6.4) per 1000 PY compared with an out-of-treatment rate of 11.5 
(95% CI: 11.1–12.0) per 1000 PY. Similarly, Ledberg (2017) reported mortality rates 
in a sample of opiate users undergoing methadone maintenance treatment was 
significantly increased compared to the general population, both during periods of 
treatment and when not in treatment. While mortality risk is higher among opioid 
pharmacotherapy clients in the first two to four weeks following treatment cessation 
(Clausen, Anchersen, & Waal, 2008; Cousins et al., 2011; Degenhardt et al., 2009) 
the initial four weeks of pharmacotherapy induction is also a time of elevated risk 
compared with remaining time in treatment. Similar patterns of elevated mortality risk 
immediately following treatment cessation have been noted in other drug using 
cohorts.   
In a cohort study of over 10,000 heroin users, mortality was measured across multiple 
treatment modalities, including methadone maintenance, therapeutic communities, 
pharmacological detoxification and treatment, and psychosocial treatments, finding 
most deaths occurred out of treatment, with the highest rate of death occurring in the 
first month out of treatment (Davoli et al., 2007). Similarly, when the effect of 
medication-free inpatient treatment (detoxification) was assessed among a Norwegian 
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group of drug users followed for eight years after treatment cessation, elevated risk of 
death was experienced in the first month following treatment discharge (Ravndal & 
Amundsen, 2010). 
 
For clients seeking treatment for alcohol use problems, both short- and long-term 
mortality risks have been identified following treatment cessation (Costello, 2006; 
Lloyd, Barratt, Ferris, Best, & Lubman, 2013; Saitz et al., 2007). Acute alcohol-
related contributors to causes of death (e.g. overdose and fatal injuries) influence 
short-term survival following treatment, while chronic conditions (e.g. cancers and 
liver disease) contribute significantly to increased mortality rates among clients 
followed up over longer periods (Costello, 2006). Ongoing engagement with support 
services, and identification of groups at elevated risk have been identified as 
important to reduce post-treatment mortality for such populations (Costello, 2006; 
Timko, DeBenedetti, Moos, & Moos, 2006). 
 
While opioid-using cohorts receiving pharmacotherapy have been studied extensively, 
there is less evidence about mortality risks during and following other types of 
treatment and for groups of clients in treatment with drugs of concern (DoCs) other 
than opioids. This study examines mortality outcomes for clients engaged in treatment 
for alcohol, opioids and other drugs across a range of treatment modalities other than 
primary pharmacotherapy, and assesses mortality both during treatment and for the 2 
years following discharge. Concerns about safety of treatment can compromise 
acceptance of treatment in the community and discourage engagement by drug users. 
By identifying periods of elevated risk, when heightened support may be required, 
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associated with different types of drug and alcohol treatment the results of this study 
can inform safer clinical practices.   
 
2 METHODS 
 
This study integrates client data from the Australian Alcohol and Drug Information 
System (ADIS) database (including detailed information regarding all specialist 
treatment) with the National Death Index (NDI; which includes detailed information 
regarding cause of death for all deaths occurring in Australia)  to examine mortality 
outcomes among a cohort of Alcohol and Other Drug treatment service clients from 
Victoria, Australia. The two databases were linked based on  partial client identifiers.   
 
2.1 Cohort 
ADIS is a register of government-funded, specialist Alcohol and Other Drug (AOD) 
treatment services (for a full list of services please see Table 1). The cohort used for 
the current study were selected based on three criteria: completion of  one or more 
courses of AOD treatment (for example, counselling, residential withdrawal) in the 
12-month period between 1 July 2000 and 30 June 2001, with first course of treatment 
(COT) starting on or after 1 January 2000;  records had to include a valid date of birth 
(required for linkage purposes) and; records had to include a start date of first COT.  
After applying these criteria the final cohort included 18,686 clients.  To enable data 
linkage, a unique identifier was created for each individual by combining  partial 
name identifiers (second two letters of first name and first two letters and last letter of 
surname), date of birth and gender (for example John Doe, 17/01/1969, male would 
be ohdoe170169m).  
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2.2 Data sources 
2.2.1 ADIS 
To ensure full capture of sequential, overlapping and/or embedded COTs we matched 
cohort codes across eight years of ADIS data. This data captured all COTs that 
terminated between 1 July 2000 and 30 June 2008. Multiple COTs were common 
among the cohort with the median of 2 (IQR 1-5) COTs. COTs could be continuous, 
indicating a change of treatment type, agency or DoC.  
 
The total number of COTs for this cohort was 89,764.  A number of steps were taken 
to clean and prepare the data for analyses. COTs were excluded if they started before 
1 January 2000 or after 1 January 2007 and overlapping COTs and consecutive COTs 
were recoded. Specifically, overlapping courses of treatment were amended so that 
the first one finished on the day the subsequent one started; both records were 
retained. Where two or more treatments started on the same day the longest running 
treatment remained for the analysis and the other treatments were removed. Data 
cleaning resulted in the removal of approximately 15% of records; a total of 76,342 
COTs were retained for the final analysis.  
 
2.2.2 National Death Index (NDI) 
Data linkage, between the ADIS cohort and NDI, was conducted by the Australian 
Institute of Health and Welfare (AIHW). The first of three linkage passes used an 
exact match unique identifier.  This process was repeated matching  only on month 
and year of birth. The final pass identified cases within ADIS where the client was 
recorded as deceased where death occurred after the last ADIS contact date. 
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Ninety-four percent of deaths (N=532) were matched with NDI during the first pass;  
10 cases (2%) were matched in the second pass;  the final 23 (4%) cases were 
matched in the third pass. 
 
2.3 Data Analysis 
Data were examined using survival analysis. All analyses were conducted using Stata 
11.  
 
2.3.1 Predictor variables 
Demographic, drug and treatment variables available in ADIS were included as 
predictors in survival time analysis. Sex, country of birth (born in Australia or not) 
and indigenous status were included as time constant predictors. Age, employment 
status (employed or not employed), living status (alone or with family/others), 
temporary or homeless accommodation status, and current involvement in the justice 
system (through community based orders, parole, bail, custody, etc.) were included as 
time-varying covariates. Other covariates in the models included primary DoC and 
injecting drug use at the start of each COT and medical and psychiatric comorbidities.  
 
We included an indicator of polydrug use. This was computed using the reported 
DoCs for multiple COTs.  Individuals who recorded different primary DoCs across 
multiple COTs were classified as polydrug users. This measure may underestimate 
polydrug use in the cohort but it has utility in identifying clients with multiple DoCs 
requiring treatment. 
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Within the ADIS database AOD treatment is classified as one of 11 types: 
counselling; residential withdrawal; other withdrawal; brokerage; outreach; specialist 
pharmacotherapy; other services; supported accommodation; aboriginal services; 
residential rehabilitation; post-withdrawal linkage. Treatment type classifications are 
defined in Table 1. We included variables to capture type of treatment received, 
number of COTs per client and reason for treatment termination. 
 
2.3.2 Crude mortality rates (CMR) and standardised mortality ratios SMR) 
All-cause CMRs are presented per 1000 person-years (PY) and were computed as the 
total number of deaths divided by the equivalent sum of person years of observation. 
Indirect all-cause SMRs for 10-year age groups were computed based on death rates 
of the Victorian population in the year 2000. To calculate CMRs and SMRs, time at 
risk (in person-years) was calculated from date of first COT (between 1 January 2000 
and 30 June 2001) to the earliest of date of death, or two years after the last COT 
ended, or 31 December 2006. Two-sided 95% confidence intervals (95% CI) were 
based on Poisson distribution. 
 
2.3.3 Factors predicting mortality 
Time-at-risk following treatment was calculated from the date of termination of last 
COT to death or censorship. Censorship occurred at the earliest of two years after last 
COT ended or 31 December 2006. The median survival time was two years. In-
treatment deaths were examined according to duration of treatment engagement for 
that COT. 
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Bivariate relationship between covariates and time-to-death were assessed using cox 
proportional hazards models. Variables that did not meet the proportional hazards 
assumption (Hosmer & Lemeshow, 1999) were split into two distinct hazard ratios 
(for year 1 and year 2) by creating ‘heaviside’ functions of the specific covariates: 
then modelled as an extended cox proportional hazards model (Kleinbaum & Klein, 
2005). When heaviside functions are used, fixed hazard ratios for specified time 
intervals are generated (Kleinbaum & Klein, 2005). In this instance, an estimate of the 
hazard ratio is calculated for the indicator variable at year 1 and year 2; that is two 
distinct hazard ratios are concurrently modelled against time to death (Hosmer & 
Lemeshow, 1999). Reassessment of the proportional hazards assumptions using these 
time-interacted variables demonstrated all models were well-specified.  
 
Only covariates with p-values <0.05 in univariate models were included as controls in 
the series of multivariate Cox proportional hazards models. These models controlled 
for age, sex, not being employed, living alone, psychiatric comorbidity, recent 
injecting and total number of COTs received. As the primary DoC may also impact 
which type of treatment an individual may seek (or be referred to) the primary DoC 
was also including in the multivariate models. As there were 10 primary DoCs 
reported (see Table 2) and a number of these had less than 1000 cases, the primary 
DoC was recoded into 5 categories when included in the multivariate models: heroin 
and other opioids; alcohol; cannabis; amphetamine; benzodiazepines, sedatives and 
other hypnotics; and other. Unadjusted and adjusted models were run separately for 
each treatment type, with the reference group defined as all other cases. 
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The Victorian Department of Human Services HREC and the AIHW Ethics 
Committee reviewed and approved all aspects of the project. 
 
3 RESULTS 
Treatment data of 18,686 individuals was analysed, representing 69,270 person-years 
over 89,764 COT.  Two thirds (65%) of the cohort were male and median age at start 
was 28 years (IQR 21–36).  
 
Table 1 
 
Counselling was the most commonly received treatment type (Table 1). Residential 
withdrawal, other withdrawal and brokerage (case managed assessment, referral and 
linkage) services were also common.  The median number of COTs per client was 2 
(IQR 1–6) and median length of each COT was 31 days (IQR 10–74), although clients 
spent much longer in treatment overall – with a median of 115 days in treatment (IQR 
36–295). Substantially more time was spent out of treatment: the median time out of 
treatment was 794 days (IQR 731–1575) or 2.2 years (IQR 2.0–4.3).  
 
Table 2 
 
The primary DoC varied across treatment types, with heroin and other opioids, 
alcohol and cannabis most commonly cited. While heroin and other opioids were 
commonly noted as the primary DoC for residential withdrawal, other withdrawal and 
residential rehabilitation (45%, 34% and 48% respectively), alcohol (33%, 36% and 
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34% respectively) and cannabis (12%, 17% and 8% respectively) constituted sizable 
proportions of COTs (Table 2). 
 
Table 3 
 
Table 3 highlights that the overall in-treatment CMR (12.4; 95% CI: 10.5–14.5) was 
significantly higher than the overall out-of-treatment (post-treatment) CMR (7.4; 95% 
CI: 6.7–8.1). This pattern was also reflected in SMRs: overall in-treatment SMR 
(10.7; 95% CI: 9.12–12.6) overall out-of-treatment SMR (6.1; 95% CI: 5.5–6.7). 
However, this difference was not as clear when comparing CMR and SMR in-
treatment and out-of-treatment rates at particular treatment durations. For example, Z-
tests and overlapping confidence intervals indicate that CMR estimates in treatment at 
the first month and second month of treatment did not significantly differ from CMR 
estimates out-of-treatment at the first month and the second month (Payton, 
Greenstone, & Schenker, 2003; Schenker & Gentleman, 2001). When divided further 
by treatment time, risk of death was not significantly different in the first two months 
after leaving treatment compared with any of the in-treatment time periods examined.  
 
Table 4 and Figure 1 and Figure 2  
 
The unadjusted hazard of death for clients discharged from residential withdrawal was 
two and a half times the rate of all other clients (148% increase – 95% CIs: 94%-
217%). While there was some diminution of effect in adjusted analyses, rate of death 
for clients who were discharged from residential withdrawal remained significantly 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 13 
elevated – at more than double the rate of all other clients (a 118% increase – 95% 
CIs: 68–185%).  
 
After adjustment, clients whose last COT was counselling experienced a significantly 
lower hazard of death in the first year of follow-up compared with all other cases 
(42% decrease – 95% CIs: 25–55%) (Table 4 and Figure 1). However, there was no 
significant protective effect found for counselling in the second year following 
treatment cessation. There were no other statistical differences between the remaining 
treatment modalities (Table 4 and Figure 2).   
 
4 DISCUSSION  
While the benefits of AOD treatments are evident, studies also show that drug users 
experience elevated mortality risk within the four weeks immediately following 
treatment cessation (Clausen et al., 2008; Cousins et al., 2011; Degenhardt et al., 
2009). To date research on this phenomenon has largely focussed on opioid-users 
engaged in pharmacotherapy (Clausen et al., 2008; Davoli et al., 2007; Degenhardt et 
al., 2009). As concerns about treatment safety may discourage engagement by drug 
users, identifying periods of elevated risk and providing extra support during these 
periods is an important public health endeavour. Here we extend on previous studies 
by presenting CMRs and SMRs for a cohort of specialist alcohol and other drug 
treatment clients who experienced problems with a wide range of drug types, and 
have sought treatment across several modalities. By focussing on a range of AOD 
treatment services and drug types our study identifies key differences in risk across 
drug types and treatment modalities. We summarize the results in three key findings.  
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First, we find that the overall CMRs and SMRs for clients whilst in treatment and 
clients in the first two months after treatment cessation were significantly greater than 
the overall rate. While previous studies have identified risk of death as being more 
elevated out-of-treatment (Davoli et al., 2007; Degenhardt et al., 2009; Ledberg, 
2017), most indicate greatest risk of death is in the first month following treatment 
cessation (Clausen et al., 2008).  Our results support these findings, with the highest 
risk of death in the first month following treatment cessation when examining all 
treatment types combined (Davoli et al., 2007; Degenhardt et al., 2009). Yet, our 
finding that CMRs and SMRs for clients in treatment were significantly higher than 
for clients who had ceased treatment when combining all time periods was in contrast 
to previous research. While most previous studies have focused primarily on 
populations of heroin users, and have largely drawn on opioid pharmacotherapy 
cohorts to examine relationships between treatment and mortality risk, our sample is 
diverse in both treatment modalities and drug types. Studies on opioid users engaged 
in substitution pharmacotherapy have noted an elevation in risk at transition periods, 
in the early stages of treatment and immediately following treatment cessation (Buster 
et al., 2002; Degenhardt et al., 2009). This is likely owing to the nature of opioid 
substitution therapy (OST), which can be considered a maintenance treatment or 
temporary approach to managing physiological withdrawal symptoms during 
detoxification (Amato, Minozzi, Davoli, & Vecchi, 2011). If abstinence is desired by 
a client undergoing OST, typically psycho-social based treatments are employed 
while OST is tapered and eventually eliminated. These psycho-social treatments 
include behavioral treatments such as counselling and family therapy (Amato et al., 
2011 & Vecchi, 2011). Thus, the elevated risk period immediately following 
treatment cessation that has been identified in previous research may indeed point to 
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elevated risk during post-OST abstinence-based treatments.  Our findings 
demonstrate a need to consider time in-treatment as also being characterised by 
increased mortality risk. We suggest more research is required to fully understand 
mortality risk during this period.  
 
 
Second, we find that clients discharged from residential withdrawal were at increased 
risk of death in the first year out of treatment compared with all other clients in 
cohort. This is supported by prior research (Ravndal & Amundsen, 2010; Strang et al., 
2003). However, the magnitude of the finding raises questions regarding what factors 
might drive such an elevation in risk of death, and although the analyses controlled 
for a range of covariates, unmeasured aspects of severity of substance issues and 
complexity of treatment pathways may contribute to these results. Further, as death 
risk has been calculated based on last treatment type, we are unable to discern from 
this study whether clients who transition from residential withdrawal to another 
treatment modality, such as community-based support, have better outcomes. Further 
research is needed to examine treatment and client trajectories in terms of suites of 
treatment and support, and also client profiles of severity, complexity, risk and 
support. 
 
Third, clients discharged from counselling experienced a decreased risk of death in 
the first year out of treatment compared with all other clients. This significant finding 
may indicate protective effects of the most commonly used treatment type in the 
treatment system, or may reflect a client population experiencing fewer barriers to 
recovery. The severity of substance use issues experienced by clients in the cohort is 
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likely to vary significantly and this finding may reflect a propensity for counselling 
clients to present with less complex cases then those clients diverted to other 
treatments such as residential programs. Still, these findings are promising and 
highlight the potential importance of facilitating clients’ engagement with counselling 
services both as a primary treatment modality and following detoxification.  
 
Understanding protective and risk factors in relation to treatment options across 
diverse populations is essential, and is highlighted by the high proportions of clients 
accessing AOD treatment services for drugs other than opioids – with alcohol and 
cannabis representing primary DoCs for the majority of COT in Australia (Australian 
Institute of Health and Welfare, 2015 ).This study offers insight into diverse AOD 
treatment populations and is a significant new contribution to evidence in an 
Australian context. The findings presented here have significant policy and practice 
implications for assessment and support of people seeking AOD treatment regarding a 
need for enhanced engagement and support following treatment cessation, and 
emphasise a need for an evidence-based approach to treatment provision and delivery 
that incorporates an outcome monitoring framework.   
 
4.1 Limitations 
Despite adopting a robust linkage process that yielded a sufficiently large cohort for 
analysis, the findings presented here may underestimate mortality by missing ADIS 
clients who had incomplete data and were unable to be matched to NDI.  We 
acknowledge that the data used here is somewhat dated, however, we also note 
continuity in AOD treatment services in Australia in the intervening years(Australian 
Institute of Health and Welfare, 2016).  While the National Drug Strategy 2004-2009 
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was reviewed in 2009, funding structures for AOD treatment services were continued 
in the National Drug Strategy 2010-2015.  The types of AOD treatment services 
utilised in Australia have remained relatively unchanged over the last decade thus we 
do not anticipate the age of the data to impact the relevance of the findings 
(Australian Institute of Health and Welfare, 2016). 
A limitation of the data worth noting is that key indicators of the severity and 
complexity of the client’s substance use issues were not recorded in ADIS; these 
factors are likely to influence the survival of drug treatment clients. For example, age 
of first drug use and first injection are important covariates for mortality (Bird & 
Hutchinson, 2010). Lifestyle factors and engagement with other agencies including 
mental health services and the criminal justice system are also likely to play a 
significant role in mortality risk; this information was not available in ADIS. More 
data regarding client journeys through treatment over time would be useful in 
determining patterns of treatment engagement that influence client outcomes. 
A final limitation relates to ADIS coding practices; treatment classification is 
interpreted by the treating agency thus some discrepancies across services may exist. 
Furthermore, coding practices for predictor variables may have changed 
systematically over the period examined resulting from policy changes – e.g., 
additional DoCs, and different categories of DoCs, have been adopted during this 
time. To minimise the impact on results, only complete and consistently accurate 
variables were included in analyses.  
 
4.2 Conclusion 
Survival following engagement in AOD specialist treatment is greatest following 
counselling treatment, whilst residential withdrawal represented the treatment 
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modality with poorest survival outcomes for clients where this was their last treatment 
type – which may reflect a lack of sufficient aftercare, or the comparative complexity 
of this client group. There is a need to explore the role of individual, treatment and 
social factors that may contribute to mortality following treatment, and opportunities 
to enhance support for AOD clients during and following treatment to improve 
outcomes. Through implementation of evidence-based strategies that enhance existing 
treatment modalities, and engage clients throughout the recovery process, there is 
great capacity to improve health of individuals, success of treatment, and reduce the 
impact of drug use on the community.  There is an urgent need to better understand 
specific risks and factors contributing to elevated mortality risk, including causes of 
death for clients while engaged in treatment, and also following treatment, to ensure 
that the AOD system provides the best outcomes for its client populations. 
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Figure 1: Kaplan-Meier estimates by selected treatment types: Counselling and 
residential withdrawal 
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Figure 2: Kaplan-Meier estimates by selected treatment types: Counselling and 
residential withdrawal 
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Table 1: Treatment types received by 18,686 clients over 69,270 person-years 
Types of treatment Definition Frequency % of total % of known 
Counselling Counselling includes cognitive behaviour therapy, brief intervention, 
relapse intervention and motivational interviewing which can be 
individual, group or family therapy, or a combination. 
35,806 39.9 40.0 
Residential 
Withdrawal 
Residential withdrawal treatment programs refers to treatment within an 
inpatient withdrawal unit or hospital with access to medical staff, 
medications and continuous monitoring. 
12,796 14.3 14.3 
Other Withdrawal Other withdrawal programs are withdrawal management/support 
programs for individuals who no longer, or do not require inpatient 
withdrawal management.  
10,734 12.0 12.0 
Brokerage Brokerage treatment models are case management based and seek to 
identify the client’s needs and refer clients to appropriate treatment; does 
not usually include ongoing monitoring. 
9,545 10.6 10.7 
Outreach Outreach treatment occurs in an outreach environment, such as any 
private or public location, excluding a client’s home or usual place of 
residence  
8,198 9.1 9.1 
Specialist 
Pharmacotherapy 
Specialist pharmacotherapy refers to the administration of agnostic 
medications, such as methadone and buprenorphine, used as maintenance 
therapies or relapse prevention. 
2,569 2.9 2.9 
Supported 
Accommodation 
Supported accommodation refers to services primarily concerned with 
providing accommodation; some support may be available such as an 
agency worker who can be called for emotional support. 
2,404 2.7 2.7 
Aboriginal Services Aboriginal services refers to a range of treatment interventions for 
Aboriginal and Torres Strait Islander peoples, including: evidence-based 
mainstream intervention that have had culturally specific practice 
integrated into them. 
2,067 2.3 2.3 
Residential Residential rehabilitation refers to intensive treatment programs 1,636 1.8 1.8 
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Rehabilitation conducted in a residential setting typically offering a mixture of one-on-
one, group work, peer support and team/community building processes. 
Post Withdrawal 
Linkage 
Post withdrawal linkage services provide withdrawal care planning, 
including relapse prevention and linkages to external support networks 
designed to address the client’s psychosocial needs. 
1,325 1.5 1.5 
Other Services  2,541 2.8 2.8 
Total known  89,621 99.8 100.0 
Unknown  143 0.2  
Total  89,764 100.0  
NOTES: Definitions sourced from Australian Institute of Health and Welfare (2014).
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Table 2: Primary drug of concern across treatment types 
Types of treatment % Heroin and 
other 
opioids 
Alcohol Cannabis Amphet-
amine 
Other 
psycho-
stimulants 
and 
hallucin-
ogens 
Benzo-
diazepines, 
sedative and 
hypnotics 
Nicotine Volatile 
substances 
Other Unknown Total 
N 
Counselling  36.6 36.1 15.3 5.3 0.4 2.7 0.6 0.6 1.2 1.0 35,806 
Residential withdrawal  45.2 33.4 12.2 3.9 0.3 3.8 0.1 0.8 0.3 0.0 12,796 
Other withdrawal 34.3 35.7 17.0 5.1 0.4 5.5 0.3 0.4 0.5 0.8 10,734 
Post withdrawal linkage 48.2 26.9 15.0 6.3 0.7 1.6 0.0 0.2 0.5 0.7 9,545 
Outreach 50.2 11.5 24.2 4.8 0.9 1.6 0.8 3.1 1.3 1.6 8,198 
Brokerage 90.3 3.1 1.0 1.4 0.1 1.9 0.0 0.0 1.3 0.8 2,569 
Aboriginal services 47.2 29.8 13.1 3.5 0.4 1.8 0.4 1.0 0.9 1.9 2,541 
Specialist pharmacotherapy 51.9 23.5 14.8 6.6 0.2 1.6 0.2 0.2 0.5 0.5 2,404 
Residential rehabilitation 10.4 69.5 9.5 4.4 0.1 1.1 0.6 2.6 1.0 0.7 2,067 
Supported accommodation 48.3 34.4 7.9 7.6 0.3 1.0 0.0 0.1 0.1 0.3 1,636 
Other services 26.4 46.4 17.9 5.0 0.5 2.6 0.1 0.2 0.6 0.2 1,325 
Unknown 30.1 33.6 25.2 8.4 2.8 0.0 0.0 0.0 0.0 0.0 143 
Total N 37,456 28,596 13,603 4,541 414 2,538 355 741 775 745 89,764 
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Table 3: Crude mortality rates and standardised mortality ratios by year, in-treatment and out-of-treatment (N = 18,686) 
 CMR SMR 
 Person-years Observed 
deaths 
Rate 95% CI In vs Out treatment† Expected 
deaths 
Rate 95% CI In vs Out treatment† 
Year of follow-up          
2000 4,806 69 14.4 11.3–18.2  5 12.9 10.2–16.3  
2001 17,282 123 7.1 6.0–8.5  20 6.1 5.1–7.3  
2002 17,400 126 7.2 6.1–8.6  21 5.9 5.0–7.0  
2003 10,642 80 7.5 6.0–9.4  13 6.2 5.0–7.7  
2004 7,707 65 8.4 6.6–10.8  9 7.0 5.5–8.9  
2005 6,364 60 9.4 7.3–12.1  8 7.6 5.9–9.8  
2006 5,068 47 9.3 7.0–12.3  6 7.2 5.4–9.6  
 Overall in treatment    11,898 147 12.4 10.5–14.5 Pr(|Z|=4.612) <0.001 14 10.7 9.1–12.6 Pr(|Z|=4.639) <0.001 
First month in course of treatment 4,401 52 11.8 9.0–15.5 Pr(|Z|=0.957) =0.830 5 10.4 7.9–13.6 Pr(|Z|=0.799) =0.788 
Second month in course of treatment 2,516 29 11.5 8.0–16.6 Pr(|Z|=0.137) =0.554 3 9.9 6.9–14.3 Pr(|Z|=0.155) =0.562 
Remaining time in course of treatment 4,982 66 13.2 10.4–16.9 * 6 11.4 9.0–14.5  
Overall out of treatment 57,372 423 7.4 6.7–8.1  70 6.1 5.5–6.7  
First month out of treatment 4,088 58 14.2 11.0–18.4  5 12.2 9.5–15.8  
Second month out of treatment 3,357 40 11.9 8.7–16.2  4 10.3 7.6–14.1  
Third to twelve month out of treatment 24,412 186 7.6 6.6–8.8  29 6.4 5.6–7.4  
Remaining time out of treatment 25,515 139 5.4 4.6–6.4  32 4.3 3.7–5.1  
Overall cohort 69,270 570 8.2 7.6–8.9  83 6.8 6.3–7.4  
Note. All rates per 1,000 person-years. 
†
 Z-test: (       ) (√(√            ⁄ )
 
 (√            ⁄ )
 
)⁄  . * Comparison between in treatment and out treatment for 
‘remaining time in course of treatment’ is not compared due to different time periods. 
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Table 4: Most recent treatment type and associated risk of death 
Treatment type Per cent Unadjusted  
hazard ratio 
(N=17,820) 
95% CI Adjusted  
hazard ratio 
a 
(N=14,880) 
95% CI 
Counselling 
b
 52     
 In Year 1 28 0.72 ** 0.57–0.91 0.58 *** 0.45–0.75 
 In Year 2 24 1.12 0.80–1.56 0.93 0.64–1.37 
Residential withdrawal 
b
 9 2.48 *** 1.94–3.17 2.12 *** 1.62–2.79 
Other withdrawal 11 1.31 1.00–1.73 1.17 0.86–1.59 
Post withdrawal linkage 1 1.13 0.36–3.50 0.75 0.24–2.34 
Outreach 8 0.35 *** 0.20–0.61 0.92 0.52–1.63 
Brokerage 11 0.69 * 0.48–0.99 0.90 0.59–1.35 
Aboriginal services 2 0.91 0.47–1.75 1.02 0.50–2.09 
Specialist pharmacotherapy 2 1.60 0.90–2.84 1.13 0.57–2.23 
Residential rehabilitation 1 2.11 * 1.09–4.08 1.73 0.88–3.37 
Supported accommodation 2 0.56 0.23–1.36 0.62 0.26–1.50 
Other services 2 0.39 0.14–1.03 0.57 0.21–1.53 
Note. * p < .05, ** p < .01, *** p < .001. 
a
 Complete-case analysis adjusted for age, gender, not 
employed, lives alone, psychiatric comorbidity, recent drug injection, total courses of treatment and 
primary drug of concern (heroin and other opioids; alcohol; cannabis; amphetamines; benzodiazepines, 
sedatives and hypnotics; and other). 
b
 Variables that did not meet the proportional hazards assumption 
were stratified by follow-up year using heaviside functions. 
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Highlights 
 This study examines crude (CMR) and standardised mortality rates (SMR) in 
sample of alcohol and drug treatment clients. 
 CMRs and SMRs were highest in treatment and in first two months after 
treatment cessation. 
 Clients discharged from residential withdrawal were at increased risk of death 
in the first year out of treatment compared to the cohort. 
 Clients discharged from counselling experienced lower risk of death in the 
first year out of treatment compared to the cohort. 
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